金陵药业(000919) - 2015 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2015 was ¥712,972,532.63, representing a 12.10% increase compared to ¥636,029,342.61 in the same period last year[8]. - Net profit attributable to shareholders was ¥57,242,147.84, a significant increase of 40.06% from ¥40,869,293.48 year-on-year[8]. - The net profit after deducting non-recurring gains and losses decreased by 4.77% to ¥38,959,109.47 from ¥40,908,478.44 in the previous year[8]. - Basic and diluted earnings per share increased by 40.07% to ¥0.1136 from ¥0.0811 year-on-year[8]. Cash Flow - The net cash flow from operating activities was negative at -¥27,872,984.43, worsening by 154.12% compared to -¥10,968,313.37 in the same period last year[8]. - Net cash flow from operating activities decreased by 154.12% year-on-year, primarily due to increased cash payments to employees[17]. - Net cash flow from investing activities increased by 110.45% year-on-year, as cash recovered from investments exceeded cash paid for investments[18]. - Net cash flow from financing activities decreased by 97.49% year-on-year, mainly due to reduced cash received from borrowings[18]. Assets and Shareholder Information - Total assets at the end of the reporting period were ¥3,597,515,418.98, a slight decrease of 0.68% from ¥3,622,217,110.96 at the end of the previous year[8]. - Net assets attributable to shareholders increased by 2.47% to ¥2,377,953,915.16 from ¥2,320,642,964.82 at the end of the previous year[8]. - The total number of ordinary shareholders at the end of the reporting period was 26,534[12]. - The largest shareholder, Nanjing XG Investment Group Co., Ltd., held 45.23% of the shares, totaling 227,943,839 shares[12]. Investments and Expenses - The company reported non-recurring gains of ¥18,283,038.37, which included a non-operating income of ¥12,116,753.49 from financial assets[9]. - Prepayments decreased by 33.45% compared to the beginning of the year, mainly due to reduced procurement in advance payment form[16]. - Non-current assets due within one year increased by 100% compared to the beginning of the year, primarily due to increased investments in trust products by a subsidiary[16]. - Construction in progress rose by 37.75% compared to the beginning of the year, attributed to increased construction projects by a subsidiary[16]. - Management expenses increased by 32.14% year-on-year, mainly due to the consolidation of a new subsidiary[17]. - Financial expenses surged by 132.79% year-on-year, primarily due to increased interest expenses and decreased interest income[17]. - Investment income rose by 86.01% year-on-year, mainly from the gain on the transfer of 100% equity in a subsidiary[17]. Other Information - The company has ongoing commitments related to equity interests in subsidiaries, ensuring competitive advantages through potential acquisitions[19]. - The company reported a total investment of 163,449,000 in securities, with a year-on-year increase of 50,192,300[22]. - The company holds 362,500 shares of Nanjing Bank, representing 0.01% of total shares, with a book value of 5,383,125[23]. - There were no derivative investments during the reporting period[24]. - The company did not engage in any research, communication, or interview activities during the reporting period[25].